Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
11:17am, Friday, 27'th Sep 2024
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
09:39am, Friday, 27'th Sep 2024
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Fr
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
09:35am, Friday, 27'th Sep 2024
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
09:35am, Friday, 27'th Sep 2024
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlle
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
07:00am, Friday, 27'th Sep 2024
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two l
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
04:05pm, Thursday, 26'th Sep 2024
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursda
Final Trades: Trane Tech, American Tower, Regeneron and Taiwan Semi
01:19pm, Wednesday, 25'th Sep 2024
The Investment Committee give you their top stocks to watch for the second half.
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
08:00am, Wednesday, 25'th Sep 2024
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio, including Eylea, Dupixent, and Libtayo, and a robust investigational pipeline. Despite legal setbacks from Amgen's Eylea bi
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
02:21pm, Tuesday, 24'th Sep 2024
Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.‘s REGN effort to prevent the sale of Amgen Inc‘s AMGN Eylea biosimilar.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
02:11pm, Tuesday, 24'th Sep 2024
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
Winners & Losers: Las Vegas Sands, FMC Corp, Regeneron and Palantir
01:19pm, Tuesday, 24'th Sep 2024
The Investment Committee highlight some of today's winners and losers.
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
12:47pm, Tuesday, 24'th Sep 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN). But which of these two stocks
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
02:45pm, Monday, 23'rd Sep 2024
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion
